The fight against HIV in Kenya has received a major boost following the approval of lenacapavir, a long-acting injectable HIV prevention drug.
Kenya is among the first nine African countries set to introduce lenacapavir by early January 2026, after WHO approved the twice-yearly jab as a highly effective method in curbing new HIV infections.
Lenacapavir received approval from the U.S.
Food and Drug Administration (FDA) in June 2025 and has been subsequently endorsed in the updated World Health Organisation (WHO) guidelines on long-acting HIV prevention, released in July 2025.
